TY - JOUR
T1 - Effectiveness of inactivated influenza vaccine in children by vaccine dose, 2013–18
AU - Shinjoh, Masayoshi
AU - Sugaya, Norio
AU - Furuichi, Munehiro
AU - Araki, Eriko
AU - Maeda, Naonori
AU - Isshiki, Kyohei
AU - Ohnishi, Takuma
AU - Nakamura, Shoko
AU - Yamada, Go
AU - Narabayashi, Atsushi
AU - Nishida, Mitsuhiro
AU - Taguchi, Nobuhiko
AU - Nakata, Yuji
AU - Yoshida, Makoto
AU - Tsunematsu, Kenichiro
AU - Shibata, Meiwa
AU - Munenaga, Takeshi
AU - Hirano, Yasuhiro
AU - Ookawara, Ichiro
AU - Sekiguchi, Shinichiro
AU - Kobayashi, Yasuaki
AU - Yamaguchi, Yoshio
AU - Yoshida, Naoko
AU - Mitamura, Keiko
AU - Takahashi, Takao
N1 - Funding Information:
T.T. has received speakers’ honoraria from Daiichi Sankyo, Japan, GlaxoSmithKline K.K., United Kingdom, Japan Vaccine, Japan, Pfizer Japan, Japan, and MSD K.K, United States; and grant support from Daiichi Sankyo, Japan, Japan Vaccine, Japan, Pfizer Japan, Japan, MSD K.K., United States, Takeda Pharmaceutical, Japan, and Astellas Pharma, Japan, none of which was in connection with the work presented here.
Funding Information:
We thank the members of the Keio Pediatric Influenza Research Group. No funding support. All authors: No reported conflicts of interest regarding this study. Outside this work, M.S. has received speakers? honoraria from Shionogi & Co. Japan, Sumitomo Dainippon Pharma, Japan, Japan Vaccine, Japan, Maruho, Japan, Astellas Pharma, Japan, Daiichi Sankyo, Japan and MSD KK, United States; and grant support from Janssen Pharmaceutical KK, Japan, none of which was in connection with the work presented here. N.S. has received speakers? honoraria from Astellas Pharma, Japan, Daiichi Sankyo, Japan, Denka Seiken, Japan and Takeda Pharmaceutical, Japan, none of which was in connection with the work presented here. K.M. has received speakers? honoraria from Mitsubishi Tanabe Pharma, Japan and Japan Vaccine, Japan; and manuscript fee from Denka Seiken, Japan, none of which was in connection with the work presented here. T.T. has received speakers? honoraria from Daiichi Sankyo, Japan, GlaxoSmithKline K.K. United Kingdom, Japan Vaccine, Japan, Pfizer Japan, Japan, and MSD K.K, United States; and grant support from Daiichi Sankyo, Japan, Japan Vaccine, Japan, Pfizer Japan, Japan, MSD K.K. United States, Takeda Pharmaceutical, Japan, and Astellas Pharma, Japan, none of which was in connection with the work presented here. For other authors, none declared.
Funding Information:
Outside this work, M.S. has received speakers’ honoraria from Shionogi & Co., Japan, Sumitomo Dainippon Pharma, Japan, Japan Vaccine, Japan, Maruho, Japan, Astellas Pharma, Japan, Daiichi Sankyo, Japan and MSD KK, United States; and grant support from Janssen Pharmaceutical KK, Japan, none of which was in connection with the work presented here.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/7/9
Y1 - 2019/7/9
N2 - Objectives: We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) by vaccine dose in children aged 6 months to 12 years for whom two doses are recommended in Japan to ascertain the appropriate vaccine doses. Methods: VE was assessed according to a test-negative case-control design based on rapid influenza diagnostic test (RIDT) results. Children aged 6 months to 12 years with a fever ≥38 °C who had received an RIDT in outpatient clinics of 24 hospitals were enrolled for all five seasons since 2013/14. VE by vaccine dose (none vs. once or twice, and once vs. twice) was analyzed. Results: In the dose analysis, 20,033 children were enrolled. Both one- and two-dose regimens significantly reduced cases in preventing any influenza, influenza A, and influenza B, but there was no significant difference in adjusted VE between one- and two-dose regimens overall (adjusted OR, 0.560 [95% CI, 0.505–0.621], 0.550 [95% CI, 0.516–0.586]), 0.549 [95% CI, 0.517–0.583], and 1.014 [95% CI, 0.907–1.135], for none vs. once, none vs. twice, none vs. once or twice, and once vs. twice for any influenza, respectively). Both one- and two-dose regimens significantly reduced cases with any influenza and influenza A every season. Also, both regimens significantly reduced cases of any influenza, influenza A, and influenza B among children aged 1–12 years, especially among those aged 1–5 years. In the 2013/14, 2015/16, and 2016/17 seasons, however, only the two-dose regimen was significantly effective in preventing influenza B. Both one- and two-dose regimens significantly reduced cases involving hospitalization due to any influenza and influenza A. Conclusions: Both one- and two-doses regimens of IIV were effective in preventing influenza for children aged 6 months to 12 years. The two-dose regimen was more effective against influenza B in some seasons.
AB - Objectives: We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) by vaccine dose in children aged 6 months to 12 years for whom two doses are recommended in Japan to ascertain the appropriate vaccine doses. Methods: VE was assessed according to a test-negative case-control design based on rapid influenza diagnostic test (RIDT) results. Children aged 6 months to 12 years with a fever ≥38 °C who had received an RIDT in outpatient clinics of 24 hospitals were enrolled for all five seasons since 2013/14. VE by vaccine dose (none vs. once or twice, and once vs. twice) was analyzed. Results: In the dose analysis, 20,033 children were enrolled. Both one- and two-dose regimens significantly reduced cases in preventing any influenza, influenza A, and influenza B, but there was no significant difference in adjusted VE between one- and two-dose regimens overall (adjusted OR, 0.560 [95% CI, 0.505–0.621], 0.550 [95% CI, 0.516–0.586]), 0.549 [95% CI, 0.517–0.583], and 1.014 [95% CI, 0.907–1.135], for none vs. once, none vs. twice, none vs. once or twice, and once vs. twice for any influenza, respectively). Both one- and two-dose regimens significantly reduced cases with any influenza and influenza A every season. Also, both regimens significantly reduced cases of any influenza, influenza A, and influenza B among children aged 1–12 years, especially among those aged 1–5 years. In the 2013/14, 2015/16, and 2016/17 seasons, however, only the two-dose regimen was significantly effective in preventing influenza B. Both one- and two-dose regimens significantly reduced cases involving hospitalization due to any influenza and influenza A. Conclusions: Both one- and two-doses regimens of IIV were effective in preventing influenza for children aged 6 months to 12 years. The two-dose regimen was more effective against influenza B in some seasons.
KW - Children
KW - Effectiveness
KW - Hospitalization
KW - Influenza vaccine
KW - Test-negative case control
KW - Vaccine dose
UR - http://www.scopus.com/inward/record.url?scp=85067002924&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067002924&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2019.05.090
DO - 10.1016/j.vaccine.2019.05.090
M3 - Article
C2 - 31186191
AN - SCOPUS:85067002924
SN - 0264-410X
VL - 37
SP - 4047
EP - 4054
JO - Vaccine
JF - Vaccine
IS - 30
ER -